Comparative Pharmacology
Head-to-head clinical analysis: ALUPENT versus PROVENTIL HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUPENT versus PROVENTIL HFA.
ALUPENT vs PROVENTIL-HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle, leading to bronchodilation.
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
Inhalation: 2 inhalations (0.65 mg per inhalation) every 3-4 hours, up to 12 inhalations per day. Oral: 20 mg three to four times daily.
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
The terminal elimination half-life of metaproterenol (Alupent) is approximately 2.5–5 hours after oral administration, and 2–4 hours after intravenous or inhaled routes. Its relatively short half-life supports dosing every 4–6 hours for bronchodilator effect.
Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment.
Renal excretion of unchanged drug and metabolites accounts for approximately 40-60% of the dose, with the remainder eliminated via biliary/fecal routes. Following oral administration, about 30-40% is recovered in urine as unchanged drug and glucuronide conjugates, and 50-60% in feces. After intravenous administration, renal elimination is 40-50% unchanged, with biliary excretion contributing 30-40%.
Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist